150 related articles for article (PubMed ID: 19149663)
1. Genesis of dihydropyrimidinone(psi) calcium channel blockers: recent progress in structure-activity relationships and other effects.
Singh K; Arora D; Singh K; Singh S
Mini Rev Med Chem; 2009 Jan; 9(1):95-106. PubMed ID: 19149663
[TBL] [Abstract][Full Text] [Related]
2. The new generation dihydropyridine type calcium blockers, bearing 4-phenyl oxypropanolamine, display alpha-/beta-adrenoceptor antagonist and long-acting antihypertensive activities.
Liang JC; Yeh JL; Wang CS; Liou SF; Tsai CH; Chen IJ
Bioorg Med Chem; 2002 Mar; 10(3):719-30. PubMed ID: 11814861
[TBL] [Abstract][Full Text] [Related]
3. The structure-activity relationship study on 2-, 5-, and 6-position of the water soluble 1,4-dihydropyridine derivatives blocking N-type calcium channels.
Yamamoto T; Niwa S; Ohno S; Tokumasu M; Masuzawa Y; Nakanishi C; Nakajo A; Onishi T; Koganei H; Fujita S; Takeda T; Kito M; Ono Y; Saitou Y; Takahara A; Iwata S; Shoji M
Bioorg Med Chem Lett; 2008 Sep; 18(17):4813-6. PubMed ID: 18684623
[TBL] [Abstract][Full Text] [Related]
4. The 1,4-dihydropyridine nucleus: a pharmacophoric template part 1. Actions at ion channels.
Triggle DJ
Mini Rev Med Chem; 2003 May; 3(3):215-23. PubMed ID: 12570837
[TBL] [Abstract][Full Text] [Related]
5. Quantitative structure-activity relationship study of recently synthesized 1,4-dihydropyridine calcium channel antagonists. Application of the Hansch analysis method.
Hemmateenejad B; Miri R; Akhond M; Shamsipur M
Arch Pharm (Weinheim); 2002 Dec; 335(10):472-80. PubMed ID: 12506395
[TBL] [Abstract][Full Text] [Related]
6. Discovery of alpha 1a-adrenergic receptor antagonists based on the L-type Ca2+ channel antagonist niguldipine.
Wetzel JM; Miao SW; Forray C; Borden LA; Branchek TA; Gluchowski C
J Med Chem; 1995 May; 38(10):1579-81. PubMed ID: 7752182
[No Abstract] [Full Text] [Related]
7. Structure-activity relationship study of 1,4-dihydropyridine derivatives blocking N-type calcium channels.
Yamamoto T; Niwa S; Ohno S; Onishi T; Matsueda H; Koganei H; Uneyama H; Fujita S; Takeda T; Kito M; Ono Y; Saitou Y; Takahara A; Iwata S; Shoji M
Bioorg Med Chem Lett; 2006 Feb; 16(4):798-802. PubMed ID: 16309909
[TBL] [Abstract][Full Text] [Related]
8. [Calcium antagonists of the dihydropyridine type: pharmaceutical chemistry and molecular pharmacology].
Mannhold R
Pharm Unserer Zeit; 1995 Jun; 24(3):137-53. PubMed ID: 7610109
[No Abstract] [Full Text] [Related]
9. Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions.
Uesawa Y; Takeuchi T; Mohri K
Curr Pharm Biotechnol; 2012 Jul; 13(9):1705-17. PubMed ID: 22039822
[TBL] [Abstract][Full Text] [Related]
10. QSAR, diagnostic statistics and molecular modelling of 1,4-dihydropyridine calcium antagonists: a difficult road ahead.
Mager PP; Coburn RA; Solo AJ; Triggle DJ; Rothe H
Drug Des Discov; 1992 Jul; 8(4):273-89. PubMed ID: 1445993
[TBL] [Abstract][Full Text] [Related]
11. Comparison between neural networks (NN) and principal component analysis (PCA): structure activity relationships of 1,4-dihydropyridine calcium channel antagonists (nifedipine analogues).
Takahata Y; Costa MC; Gaudio AC
J Chem Inf Comput Sci; 2003; 43(2):540-4. PubMed ID: 12653519
[TBL] [Abstract][Full Text] [Related]
12. QSAR study of 1,4-dihydropyridine calcium channel antagonists based on gene expression programming.
Si HZ; Wang T; Zhang KJ; Hu ZD; Fan BT
Bioorg Med Chem; 2006 Jul; 14(14):4834-41. PubMed ID: 16580211
[TBL] [Abstract][Full Text] [Related]
13. [Derivatives of 1,4-dihydropyridines as "priviledged structures" and their pharmacological potential].
Żorniak M; Mitręga K; Krzemiński TF
Kardiol Pol; 2011; 69 Suppl 3():100-3. PubMed ID: 22125212
[TBL] [Abstract][Full Text] [Related]
14. Discovery and evaluation of selective N-type calcium channel blockers: 6-unsubstituted-1,4-dihydropyridine-5-carboxylic acid derivatives.
Yamamoto T; Niwa S; Tokumasu M; Onishi T; Ohno S; Hagihara M; Koganei H; Fujita S; Takeda T; Saitou Y; Iwayama S; Takahara A; Iwata S; Shoji M
Bioorg Med Chem Lett; 2012 Jun; 22(11):3639-42. PubMed ID: 22560585
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, spectroscopic, DFT, and molecular docking studies on 1,4-dihydropyridine derivative compounds: a combined experimental and theoretical study.
Karthick R; Velraj G; Pachamuthu MP; Karthikeyan S
J Mol Model; 2021 Dec; 28(1):5. PubMed ID: 34889990
[TBL] [Abstract][Full Text] [Related]
16. Gene activations of CYP2B1 and CYP3A1 by dihydropyridine calcium channel antagonists in the rat liver: the structure-activity relationship.
Konno Y; Degawa M
Biol Pharm Bull; 2004 Jun; 27(6):903-5. PubMed ID: 15187443
[TBL] [Abstract][Full Text] [Related]
17. A novel dihydropyridine with 3-aryl meta-hydroxyl substitution blocks L-type calcium channels in rat cardiomyocytes.
Galvis-Pareja D; Zapata-Torres G; Hidalgo J; Ayala P; Pedrozo Z; Ibarra C; Diaz-Araya G; Hall AR; Vicencio JM; Nuñez-Vergara L; Lavandero S
Toxicol Appl Pharmacol; 2014 Aug; 279(1):53-62. PubMed ID: 24844443
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the inhibitory effect of dihydropyridines on N-type calcium channel by virtual three-dimensional pharmacophore modeling.
Ogihara T; Kano T; Kakinuma C
Arzneimittelforschung; 2009; 59(6):283-8. PubMed ID: 19634509
[TBL] [Abstract][Full Text] [Related]
19. [Interaction of 1,4-dihydropyridines with ion channels].
Veizerová L; Svetlík J; Kettmann V
Ceska Slov Farm; 2008 Apr; 57(2):58-62. PubMed ID: 18578414
[TBL] [Abstract][Full Text] [Related]
20. Active conformation of 1,4-dihydropyridine calcium entry blockers. Effect of size of 2-aryl substituent on rotameric equilibria and receptor binding.
Rovnyak G; Andersen N; Gougoutas J; Hedberg A; Kimball SD; Malley M; Moreland S; Porubcan M; Pudzianowski A
J Med Chem; 1991 Aug; 34(8):2521-4. PubMed ID: 1652021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
